Login Register Cart 0
Generic placeholder image

Current Drug Safety

Editor-in-Chief

ISSN (Print): 1574-8863
ISSN (Online): 2212-3911

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Case Report

DRESS Syndrome Associated with Liposomal Amphotericin-B in a Kidney Transplant Patient: A Case Report

Author(s): Ons Charfi*, Syrine Ben Hammamia, Imen Aouinti, Widd Kaabi, Sarrah Kastalli, Riadh Daghfous, Sihem El Aidli, Ghozlane Lakhoua and Ahmed Zaiem

Volume 18, Issue 2, 2023

Published on: 07 November, 2022

Page: [264 - 266] Pages: 3

DOI: 10.2174/1574886316666210727145646

Price: $65

Abstract

Introduction: Liposomal amphotericin B is a widely used broad-spectrum antifungal drug. It was developed to reduce nephrotoxicity and maximize the therapeutic utility of amphotericin B in the treatment of invasive fungal infections. Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) syndrome is a severe drug-induced hypersensitivity syndrome commonly associated with aromatic antiepileptic drugs. Liposomal amphotericin-B was associated with DRESS syndrome in only one case.

Case Report: We report an exceptional case of possible DRESS syndrome associated with liposomal amphotericin B in a 31-year-old male renal transplant recipient. Seventeen days after starting liposomal amphotericin B for visceral leishmaniosis, he developed a skin rash with elevated liver tests. Liposomal amphotericin B was then discontinued. A favourable outcome was slowly observed in one month.

Results and Conclusion: This case scored two (possible case) based on the criteria adopted by the European group RegiSCAR. The Naranjo score for liposomal amphotericin B was four (possible).

Keywords: Leishmaniosis, drug hypersensitivity syndrome, pharmacovigilance, amphotericin, adverse drug reaction, DRESS syndrome.

« Previous Next »
[1]
Stone RHN, Bicanic T, Salim R, William H. Liposomal Amphotericin B (AmBisome®): A review of the pharmacokinetics, pharmacodynamics, clinical experience and future directions. Drugs 2016; 7: 485-500.
[2]
Steimbach LM, Tonin FS, Virtuoso S, et al. Efficacy and safety of amphotericin B lipid-based formulations-a systematic review and meta-analysis. Mycoses 2017; 60(3): 146-54.
[http://dx.doi.org/10.1111/myc.12585] [PMID: 27878878]
[3]
Kardaun SH, Sidoroff A, Valeyrie-Allanore L, et al. Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: Does a DRESS syndrome really exist? Br J Dermatol 2007; 156(3): 609-11.
[http://dx.doi.org/10.1111/j.1365-2133.2006.07704.x] [PMID: 17300272]
[4]
Hagihara M, Yamagishi Y, Hirai J, et al. Drug-induced hypersensitivity syndrome by liposomal amphotericin-B: A case report. BMC Res Notes 2015; 8(1): 510.
[http://dx.doi.org/10.1186/s13104-015-1486-0] [PMID: 26420570]
[5]
Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30(2): 239-45.
[http://dx.doi.org/10.1038/clpt.1981.154] [PMID: 7249508]
[6]
Begon E, Roujeau JC. Syndrome d’hypersensibilité médicamenteuse ou DRESS (drug reaction with eosinophilia and systemic symptoms). Ann Dermatol Venereol 2004; 131(3): 293-7.
[http://dx.doi.org/10.1016/S0151-9638(04)93600-9] [PMID: 15107755]
[7]
Descamps V, Mardivirin L, Janela B, et al. The drug hypersensitivity syndrome (DRESS syndrome) is nothing but a viral illness. Rev Fr Allergol 2010; 50: 171-3.
[http://dx.doi.org/10.1016/j.reval.2010.01.027]

Rights & Permissions Print Cite
Article Metrics
37
2
© 2024 Bentham Science Publishers | Privacy Policy